Dyslipidemia (ABIM Review)

Think back to your residency training. Like, remember everything you were taught about the pooled cohort equations. Oh, right. The, uh, the classic fire and forget statin dosing. Exactly. The era where we explicitly abandoned absolute LDL targets and, you know, just put everyone on a high intensity statin and kind of hope for the best. Yeah, that entire mental algorithm. It was everywhere. Well, you can take that entire framework, uh, scrub it from your brain and literally throw it out the window. Welcome to another installment of the AIMIM series on evidence at the bedside. I'm Dr Taylor and I'm Dr Griffin. The newly released 2026 ACC, AHA, Dyslipidemia guidelines are officially here. And, uh, I mean, they represent a massive fundamental paradigm shift in how we practice cardiovascular medicine. They really do. And if you are prepping for the boards or honestly, like if you are just seeing patients in clinic tomorrow morning, relying on the old frameworks is going to lead to immediate clinical error. Oh, absolutely. And so that is exactly our mission for this installment of the AIMIM series. We're going to completely rewire your diagnostic and management algorithms for Dyslipidemia based on the recent guidelines. Right. Because we are not just going to read you the literature. We are going to dig into the, uh, the cellular pathophysiology of why these shifts are happening. Yeah. And translate the evidence directly to your bedside practice and point out, you know, every single trap the board examiners are currently setting for you. So true. And I think before you can prescribe a single medication or even counsel a patient on lifestyle, you must accurately calculate their baseline cardiovascular risks. Right. Because if your baseline calculation is flawed, your entire clinical management plan just crumbles exactly. And the literature has officially retired the pooled cohort equations or the PCE. They are completely gone, which is wild to think about. I know, right? In their place, the American Heart Association has introduced the prevent equations. I want to stop right there and dig into the why because the rationale behind retiring the PCE is highly testable on the wards and on the boards. Oh, heavily tested. We use the PCE for years. So why are we suddenly throwing it away? The fundamental issue is that the old pooled cohort equations drastically overestimated risk. Yeah. They were heavily derived from historical cohorts like think framing him. Think the air see study. Right. You are talking about populations of patients born before 1930, which means you have to consider the lifetime environmental and medical exposures of that specific demographic. Right. Exactly. That generation had vastly higher rates of widespread tobacco use, completely untreated or poorly treated hypertension and absolute zero exposure to modern preventive therapies. Yeah. Plus they lived through an era before any bands on trans fats and the food supply. So when you take a mathematical model built on the arteries of someone living in say 1965 and apply it to a modern 45 year old patient sitting in your clinic today, you get an artificially inflated, highly inaccurate risk score. It's just bad math for today's patients. The prevent equations fix this by deriving their data from over three million contemporary adults. Wow. Three million. Yeah. And when you actually run the numbers, the physiological shift is jarring. The prevent equations yield 10 year risk estimates that are roughly 40 to 50% lower than the old PC. That is a massive drop. And the variables themselves have also been modernized, right? To reflect our current clinical understanding. They have. You are now calculating risk for adults starting at age 30, not 40, which makes so much sense given what we see in clinic. Exactly. You still input the basics like sex, systolic blood pressure, total cholesterol, HDO cholesterol, diabetes and tobacco use. But you also must input the estimated glomerular filtration rate or EGFR and the use of statins or anti hypertensive medications. I think adding the EGFR is a brilliant physiological update. Oh, completely. Because the kidney is fundamentally a vascular organ, right? Yeah. The nephron is basically a highly sensitive capillary tough. We know that microvascular disease in the kidney is one of the earliest and most potent predictors of macrovascular atherosclerotic disease in the coronary and cerebral arteries. Yep. If the EGFR is dropping, the systemic endothelium is already suffering. Exactly. And here is a crucial update you must lock in for the exam and it really reflects a major shift in how we understand demographics and medicine. Race has been completely removed as a variable in the prevent equations, which is huge. It is. The literature firmly acknowledges that race is a social construct, not a biological one, and forcing it into a biological risk calculator actually exacerbates health disparities rather than resolving them. Right. And instead the prevent calculator offers optional inputs that allow you to hyper personalize the risk based on actual physiological and social data. Like what? Well, you can now input hemoglobin A1c, the urine album into creatinine ratio. And get this. The patient's zip code. Wait, zip code. That zip code integration is fascinating. It really is. It serves as a localized proxy for the social deprivation index. Oh, I see. Yeah, it mathematically accounts for social determinants of health. Things like food deserts, walkability, chronic environmental stress and healthcare access. And those have a profound impact on atherosclerotic risk. That makes total sense. Now, because the prevent equations yield much lower absolute numbers, the thresholds for defining risk have fundamentally shifted downward. Right. So need a new memory hook for this. Exactly. Under the reason guidelines, a 10 year risk of less than 3% is considered low risk. A 3% to less than 5% risk is borderline. 5% to less than 10% is intermediate. And anything 10% or greater is now high risk. So let's lay out the classic board trap that stems directly from these new thresholds because you see this exact trap set up on the boards constantly. And honestly, I see residents fall for it during clinic chart rounds all the time. Oh, completely. The vignette will present a 45 year old patient. You calculate their 10 year risk and it comes out to 4%. The question will ask for the next best step in management. And one of the options will prominently feature the word reassurance, right? Or like continue current lifestyle without pharmacotherapy. Exactly. And if you are still operating on the old PCE software in your brain, you will absolutely click that distractor because under the old rules, 4% was well within the low risk category. Right. But under the new prevent equations, a 4% risk falls squarely into the board line category. Reassurance is a clinical error here. So what's the right move? The correct board answer is to engage in a benefit risk discussion for lipid lowering therapy, especially if the patient has risk enhancers. The guidelines formally endorse that you can and often should consider a statin at a 4% 10 year risk. To operationalize this at the bedside, the evidence suggests a pretty clean mental framework, the CPR model. Oh, I like that. Yes, C stands for calculate the 10 year risk using the prevent equations. P stands for personalized that risk using risk enhancers. So we are talking about critical clinical variables, not explicitly captured in the math. Exactly. Like does the patient have a family history of premature atherosclerotic cardiovascular disease? Did they experience premature menopause or preeclampsia? Do they have chronic systemic inflammatory conditions like rheumatoid arthritis, lupus or psoriasis? And what's the R? R scans for reclassify, typically using a coronary artery calcium score if you're still on the fence. Right. But you know, I want to push back on this entire framework for a second because the calculate and personalized steps often leave me staring at a very skeptical patient. Oh, I know exactly what you mean. Put yourself in the clinic. You calculate a 4% risk for a 45 year old patient. They're sitting on your exam table in running gear. I mean, they run marathons. Their BMI is 22. They feel entirely invincible and you are telling them they have a borderline risk of a heart attack and might need to take a daily statin for the rest of their life. Yeah, that's a tough sell. Honestly, putting a 45 year old on a daily pill for a 4% risk feels like severe over medicalization. Are the boards really expecting us to push pharmacotherapy this early? How do you actually bridge that communication gap without the patient just losing trust in you? It is arguably one of the toughest conversations in primary care. It definitely feels like over medicalization if you restrict your view to a 10 year window. The literature emphasizes that the absolute 10 year risk is just one singular metric. And honestly, it often fails to capture the impending danger for younger adults. At the bedside, you bridge that gap by pivoting the conversation away from absolute risk and toward relative risk and lifetime exposure burden. How do you freeze that practically, though? I find patients just get lost when we start tossing around relative risk percentages. I literally draw it out for them. I will tell the patient, "You're absolute risk of a heart attack in the next 10 years is 4%. I agree with you. That sounds very low. But for a perfectly healthy 45 year old without your specific lipid profile or family history, the risk should be closer to 1%. Oh, so you anchor it against their peers? Exactly. I tell them. That means you are carrying four time, the physiological risk of your peers. And more importantly, plaque doesn't just form overnight. For a 30 year time frame, the constant exposure to those circulating lipids is going to compound, just like interest on a bad loan. That's a great analogy. You just have to reframe the conversation around the prolonged decades-long exposure to pathogenic lipoproteins. That concept of prolonged exposure brings up a critical question. We have calculated the risk. We have had the conversation. But what exactly are we measuring on that lab printout and what are the absolute numerical targets we are aiming for? Right. Let's talk about advanced biomarkers and the return of strict clinical goals. For decades, the freedwold formula was the unquestioned ironclad gold standard for estimating LDL cholesterol. It was simple math, right? Total cholesterol minus the HDL minus the treglist rides divided by five. Yeah. Every lab in the country automatically calculated it. But the literature explicitly states that the freedwold formula is no longer the preferred method. In fact, relying on it in certain scenarios is considered a diagnostic failure. So let's break down the physics of why the freedwold equation fails because the exam is going to test your understanding of its limitations relentlessly. Oh, without a doubt. The freedwold formula relies on a static mathematical ratio. It rigidly assumes that the ratio of treglist rides to very low density lipoprotein or VLDL cholesterol within a lipid droplet is always exactly five to one. Right. But human physiology is dynamic. The physical composition of a lipid particle changes based on metabolic states. Exactly. When a patient has severe hyper triglyceridemia, those VLDL particles become massively engorged with treglist rides. They swell up and the physical density of the particle shifts entirely. So that rigid five to one ratio breaks down completely. The math just fails. Yep. And conversely at very low LDL levels, the inherent error margin of the equation dominates the calculation. The freedwold formula will dangerously underestimate the true circulating LDL burden in these extremes. The boards love to set a trap here. They will present a patient with an LDL of 65 milligrams per deciliter calculated via the freedwold formula. But the patient also has treglist rides of say 280. The question will ask if this high risk patient is adequately at their LDL goal. And if you trust that static equation, you will incorrectly assume they are fully optimized and pick the option to maintain current therapy. But the boards want you to recognize that the freedwold estimation is a mirage in the setting of hyper triglyceridemia. Exactly. The correct answer will involve utilizing the Martin Hopkins equation or the Samsung NIH equation. Right. Because the Martin Hopkins equation abandons that static division by five. Instead, it uses an adjustable factor derived from a massive database of lipid profiles that adapts based on the patient's specific non-HDL cholesterol and treglist ride levels. It is vastly superior. And it is now a formal class one recommendation in the guidelines to use these newer equations. And while we are upgrading our diagnostic software, we really must talk about the biomarker that is aggressively entering mainstream primary care. Are you talking about LP little A? Yes, Lepoprotein A or LPA. You need to think of LPA as an LDL particle's evil twin. It is essentially a standard LDL particle. But it has a highly specialized Lepoprotein. A tail attached to it via a disulfide bond. And that tail is the defining pathological feature. We can use a really simple bedside analogy for this. Imagine the standard LDL particle is a tennis ball bouncing through the bloodstream. Okay, tennis ball. It can occasionally embed in the vessel wall. The Lepoprotein, a tail, acts like a strip of velcro wrapped around that tennis ball. Wow, velcro. Yeah. And it shares a striking structural homology with plezmitogen, which means it binds directly to fibrin. Oh, so it's interacting with the clotting cascade too. Exactly. So not only does this particle actively embed into the endothelium to drive out the risk of losses, but that velcro tail also inhibits clot breakdown, making it highly thrombogenic. It is a dual threat particle. And the most frustrating part for patients is that LPA levels are almost entirely genetically determined. You can run ultra-marathons, eat a perfectly pristine Mediterranean diet, and your LPA will not budge a single point. It's so unfair. It is because of this hidden inherited threat, the new guidelines are definitive. LPA must be measured at least once in every adult's lifetime to assess for this specific risk enhancer. You absolutely need to memorize the thresholds for the boards too. An LPA greater than 125 nanomoles per liter or roughly 50 milligrams per deciliter is a potent risk enhancer. Okay, 125 nanomoles per liter. Right. It confers about a 1.4 fold increase in atherosclerotic cardiovascular disease risk. And if the value is greater than 250 nanomoles per liter or 100 milligrams per deciliter, you are looking at greater than a 2 fold increased risk. So a resident asked me the other day, if statins and diet don't lower LPA, why do we even bother measuring it? Like, what is the clinical utility if we don't have an approved drug to directly lower it yet? That is the perfect clinical question. The utility is risk reclassification. You cannot fix the LPA with a statin. So you have to crush the standard LDL to compensate for the total particle burden. Oh, that makes sense. Yeah. If a patient has a borderline prevent score, but you discover an LPA of 300, they are no longer borderline. They are high risk and you immediately escalate their LDL lowering therapies to mitigate the global atherosclerotic burden. That is brilliant. Let's shift to the biomarker that is finally taking its rightful place at the center of lipid management. A polio protein B or APO B. Finally. Right. For years, APO B was relegated to the realm of specialized lipidologists. Primary care doctors ignored it. But it's officially mainstream in the evidence. You must understand the physiology of APO B to pass the boards and to adequately treat complex metabolic patients. Let's use the garbage truck analogy because it flawlessly explains the physiological necessity of APO. Okay, let's hear. Imagine the cholesterol in the blood is the actual garbage and the lipid particles, the LDLs, the VLDLs, the IDLs are the garbage trucks carrying that trash through the arteries. Okay. For decades, we have only measured the total weight of the garbage, the LDLC. But what actually causes a traffic jam and destroys the highway. It's not the total weight of the trash. It's the total number of garbage trucks clogging the road and crashing into the vessel walls. And that is exactly what APO measures. Every single arthrogenic particle in the bloodstream, whether it is an LDL, an IDL, a VLDL, or an LPA particle contains exactly one molecule of APO B100 wrapped around it. One to one. Let me repeat that because it's the fundamental concept. Exactly one APO B molecule per arthrogenic particle. Yeah. Therefore, when you order an APO B level, you are not measuring the cholesterol content inside the particles. You are getting a direct one to one count of the total number of arthrogenic particles circulating in the blood. It is the ultimate definitive measure of arthroscopic particle burden. And the boards will definitely test your knowledge of the new APO B goals. What are the numbers? For primary prevention and high risk patients, the optimal APO B goal is less than 90 milligrams per deciliter. If you are dealing with a secondary prevention patient or a patient with multiple severe risk factors, the APO B goal tightens aggressively to less than 70 or even less than 55 milligrams per deciliter. So how do we actually deploy this at the bedside? A magicia of a patient with profound metabolic syndrome, severe central obesity, and uncontrolled type 2 diabetes. Okay. A very common presentation. You look at their standard lipid panel. Their LDLC looks wonderfully reassuring. Maybe it's 75 milligrams per deciliter. But you calculate their non-HDL cholesterol and it's 140. There is massive clinical discordance. The LDL weight says low risk, but the non-HDL says high risk. This is the textbook presentation of diabetic dyslipidemia and it represents a massive blind spot if you only look at LDLC. Tell me more about that. Patients with profound insulin resistance experience complex changes in lipoprotein lipase and hepatic lipase activity. This enzymatic shift actively strips the triglycerides out of the LDL particles, leaving behind tiny, dense, cholesterol depleted particles. So the particles themselves shrink? Exactly. Because these particles are so physically small and carry very little cholesterol mass, the total LDLC weight appears deceptively low. But because there are millions of these tiny BB pellet-like particles circulating, the total atherogenic particle number is actually sky high. And those small, dense particles are highly susceptible to oxidation and easily slip right through the endothelial barrier into the intima. Yep. So when you face this clinical dyscoordance in a diabetic patient, EPO-B is your ultimate tiebreaker. You order the EPO-B and if it comes back at 115 milligrams per desolate, you know definitively that this patient's arteries are under siege by a massive fleet of small, dense particles. And they need aggressive, escalated lipid lowering therapy immediately, despite that reassuring LDLC value. That perfectly sets up our discussion of the patients who occupy the absolute highest spectrum of cardiovascular risk. We have talked about borderline risk and hidden risk. But what do we do when the lab results come back flagged and bright red? Oh, the extreme phenotypes. The boards heavily test the management algorithms for extreme phenotypes and secondary prevention. Let's define the clinical parameters. If you do a chart biopsy and see an LDL cholesterol, greater than or equal to 190 milligrams per desolate in a primary prevention patient, a siren should go off in your clinical reasoning. Right. Because an LDL greater than 190 is not just a result of eating too many cheeseburgers. Exactly. It clinically implies hetersigus familial hypercholestralemia or HFH. It's strongly just a fundamental inherited genetic defect. Pathophysiologically, you are usually dealing with a mutation in the LDL receptor gene itself. Again, a function mutation in PCS-K9 which destroys the LDL receptors, or a mutation in the APOB molecule preventing it from binding to the receptor. And the end result is always the same, right? Yep. The liver completely loses its ability to clear LDL from the bloodstream and the particles simply accumulate to toxic levels. This leads directly into a classic board trap that residents frequently trigger in real life. The exam will present a 35-year-old patient who comes into established care. They have zero medical history, their BMI is 21, and they run five miles a day. Sounds familiar. Their screening lipopanel reveals an LDL of 215 milligrams per desolate. The question will ask for. for the most appropriate next step in management. One of the highly attractive distractor options will be calculate 10-year pre-vents score to determine the need for statin therapy. - Do not fall for the anchor bias of always calculating a risk score. - Never. - Never calculate a 10-year pre-vents score for a patient with an LDL greater than 190. They completely bypass the risk calculator. - Right, their cumulative lifetime exposure to that extreme LDL level means their risk of an early myocardial infarction is so profoundly elevated that they automatically qualify for aggressive immediate pharmacotherapy. - You skip directly to step one, initiate a high intensity statin, typically a torvistatin 80 milligrams, or roastivistatin 40 milligrams. - But the clinical reality, and what the evidence dictates is that a high intensity statin alone is almost never enough for a true, he-etched patient. - Yeah, the statin might drop their LDL by 50%, taking them from 220 down to 110, but they are still not at goal. So step two, mandate's combination therapy. You will need to add, he's adamant to block intestinal absorption, or utilize a PCSK9 monoconal antibody like evlocumab or alirocumab, or utilize the newer agent, Bempidoacacid. - Your absolute goal for this primary prevention he-fish patient is an LDL strictly less than 100 milligrams per desoliter. And if they have an additional risk factor, like a strong family history of premature coronary disease, you must drive that goal down to less than 70. - Let's pivot from primary prevention to secondary prevention. The patients who have already suffered a myocardial infarction in a schemic stroke or require coronary re-vascularization. - Right, a totally different ballgame. - In this arena, the literature has brought back absolute, aggressive numerical goals. The defining mantra of the new guidelines is unequivocally. Lower is better. - For a patient at very high risk of recurrent atherosclerotic cardiovascular disease events, the secondary prevention goal is strictly an LDL of less than 55 milligrams per desoliter. - Which is incredibly low. I constantly get pushed back from trainees on this. They will see a patient on high intensity statin, zedin-neeb, and a PCSK9 inhibitor. And the achieved LDL comes back at like 22 milligrams for desolation. - Yeah, and the resident panics. - Exactly. The resident gets nervous and asks, should we back off the therapy? Is the patient's brain gonna starve for cholesterol? Are they gonna stop synthesizing hormones? - It is a valid physiological concern, but the evidence overwhelmingly dismisses it. You must know for the boards that there is zero clinical signal to suggest deescalating therapy, even when the achieved LDL drops below 30 or even below 20 milligrams per desoliter. - Hey, really? No issues at all. - None. Because the brain synthesizes its own cholesterol denovo, it does not rely on circulating hepatic LDL crossing the blood brain barrier. Massive, randomized trials like Fourier and Odyssey outcomes demonstrated exceptional safety profiles at these incredibly low levels. - So you maintain the aggressive combination therapy to maximize atherosclerotic plaque stabilization and regression? - Exactly. Keep the pedal down. - Now let's dissect the pharmacology of Bempodoric acid. 'Cause the board's gonna test its mechanism of action and honestly, it is an incredibly useful tool when you're standing at the bedside of a frustrated patient. - Oh, it's a game changer. Bempodoric acid is an ATP citrate-lase inhibitor. It works in the cytosol, directly upstream of HMG-CoA reductase in the complex cholesterol biosynthesis pathway. - The precise mechanism of action is a phenomenal example of targeted drug design and it directly addresses one of our biggest clinical headaches. Staten-associated muscle symptoms or SAMs. - Yep. You will inevitably encounter patients who absolutely refuse to ever touch a statin again because they developed debilitating myoges or true myopathy. For years, we had very few oral options for these patients. - Bempodoric acid is the perfect bedside pivot. - I love explaining the pharmacology of this drug to patients because it instantly validates their prior bad experience with statins while offering a physiologically sound alternative. - Yeah. - To understand why it works, you have to realize that Bempodoric acid is administered as an inactive pro drug. - Right, to become pharmacologically active, it requires a very specific activating enzyme called very long chain, a silco-A synthetase-1 or ACS-VL-1. This is where the physiological elegance shines. That activating enzyme, ACS-VL-1, is highly expressed in the hepatocytes of the liver. But crucially, it is almost completely absent in human-skilled-a-muscle tissue. - That's the magic right there. - Therefore, when the patient's wall is Bempodoric acid, it circulates internally until it reaches the liver where it is activated and successfully shuts down hepatic cholesterol synthesis, leading to LDL receptor upregulation. - And because the drug cannot be activated in the skeletal muscle, it remains completely inert there. Fundamentally avoiding the biochemical pathways that trigger statin-induced myelages, it provides powerful LDL reduction without the muscle toxicity. - It's so brilliant. Now, we have spent an incredible amount of time talking about suppressing the LDL particle. But what happens when you do everything right? The LDL is perfectly controlled at 60, where you pull up the lab results and the triglycerides are completely deranged. - Oh. - They aren't just slightly elevated at 160. They are 800 or 1500. Statins are not gonna save you from what comes next. Let's dig into taming the triglycerides. - When you encounter hyper-traglyceridemia, your diagnostic reasoning must fundamentally shift. You cannot treat all elevated triglycerides the same way. - All right. - The evidence mandates that you mentally divide the condition into two distinct clinical buckets based on the absolute value, because the underlying pathophysiology and the immediate clinical threats are completely different. - So bucket number one is moderate hyper-traglyceridemia. Defined as triglycerides between 150 and 499 milligrams per desulator. Bucket number two is severe hyper-traglyceridemia. Defined as triglycerides greater than 500, and especially when they cross the 1000 mark. - Let's start with bucket one. When the triglycerides are, say, 300, what is the primary threat to the patient? - In bucket one, the primary clinical threat remains atherosclerotic cardiovascular disease. The moderately elevated triglycerides are basically a surrogate marker for circulating atherogenic remnant particles. Those VLDLs and IDLs that are driving plaque formation. - And because the primary threat is long-term ASCVD, your first line therapy remains a statin to reduce the total APOB particle burden. - But when you cross into bucket two, when the triglycerides surge past 500 and into the 1000s, the primary clinical threat violently shifts. The immediate life-threatening concern is no longer a slow-growing plaque causing a heart attack 10 years from now. - Right. The immediate threat is acute hemorrhagic pancreatitis tomorrow. - The physics of the blood fundamentally change. At triglyceride levels of 1500, the blood serum visually looks like milk due to the massive accumulation of massive chylomicrons. - It's terrifying to see these chylomicron particles become so incredibly large and so numerous that they physically alter blood viscosity. They literally lodge into and obstruct the microscopic capillary beds of the pancreas. - Wow. - Consulting localized esteemia, combined with the release of toxic free fatty acids by pancreatic liposes, triggers massive auto-digestive inflammation. - Because the imminent threat is acute pancreatitis, your therapeutic priorities shift completely. Statins simply do not lower triglycerize powerfully enough to avert this crisis. In bucket two, you must rapidly deploy fibrates and high dose prescription omega-3 fatty acids as your first line agents to clear the chylomicrons. - This vital dichotomy between bucket one and bucket two sets up one of the most insidious, frequently tested board traps in the entire internal medicine curriculum. - I know exactly the one you're talking about. - Right. The clinical vignette will present a patient with diabetes who is already taking it or for a satin. Their latest lipid panel shows an LDL perfectly at goal, but their triglycerides are hovering at 250 milligrams per desoliter. - So they're in bucket one. - Exactly. The question explicitly asks, which of the following medications should be added to maximally reduce this patient's risk of a future cardiovascular event? The options will inevitably include Jim Fee Brazil or Phino Fibrate. - Do not click the Fibrate. Adding a Fibrate to a statin does absolutely nothing to improve ASCVD outcomes. - Nothing. - We have massive definitive clinical trials proving this look at the prominent trial or the Accord Lipid trial. Fibrates will successfully lower the triglyceride number printed on the lab report, which makes the physician feel good, but they will not stop the patient from having a catastrophic stroke or a myocardial infarction. - Exactly. Adding a Fibrate to a statin when triglycerides are only 250 is just exposing the patient to an increased risk of myocytis and renal dysfunction for zero clinical benefit. - So if the Fibrate is the wrong answer, what is the right answer to lower the cardiovascular risk in that patient? The high yield board fact is that you should add Icospinethal, often abbreviated as IP. - The data from the Reducyte trial completely changed the landscape here. Icospinethal is not an over-the-counter fissioil supplement. It is a highly purified, prescription grade, Icospininoic acid or EPA. Inpatients with established cardiovascular disease or diabetes with multiple risk factors, whose triglycerides remain persistently above 150 despite maximized statin therapy. Adding Icospinethal significantly reduces major adverse cardiovascular events. - It is crucial to understand how it works because it's not just about lowering the triglyceride number. The EPA molecule actually embeds itself deep into the lipid bilayer of the endothelial cell membranes and the membranes of the circulating lipoproteins. - Oh, that's fascinating. - By physically integrating into the cellular architecture, it physically stabilizes the membrane, making it highly resistant to oxidative stress and dramatically reducing localized vascular inflammation. It stabilizes the vulnerable plaque itself. - While we are discussing triglycerides, you also need to know the brain, new targeted therapy for the most extreme, terrifying genetic form of this disease. Familiar Pylemmicronymia syndrome or FCS. FCS? Yeah. These unfortunate patients have inherited genetic defects in lipoprotein lipase or LPL, the enzyme responsible for clearing chylamicrons. Without LPL, their triglycerides are chronically in the thousands and they suffer from recurrent devastating attacks of pancreatitis despite incredibly strict near zero fat diets. It's awful, but the recent guidelines introduce a paradigm shifting therapy for FCS Olazarcin. It is an Oposy3 inhibitor. Let's talk about how that works. To understand this, you need to know what Aposy does. Under normal physiological conditions, Aposy3 acts as the molecular brakes on lipoprotein lipase activity. It slows clearance down. Okay, the brakes. By utilizing an anti-sense oligonucleotide to knock out the production of Aposy3, Olazarcin effectively cuts the brakes. Wow, so even in patients with defective LPL pathways, removing this inhibition allows for the rapid clearance of those massive chylamicrons. Exactly. Dramatically lowering triglyceride levels and profoundly reducing the risk of fatal pancreatitis. That is incredible. But translating this complex liponology back to the BISI hospital ward, we really have to talk about secondary causes. When you see a triglyceride level of 800, your very first reflex should not be to reach for your prescription pad to write for a fibrate. No, absolutely not. Your first reflex must be a rigorous hunt for secondary reversible causes. Before you diagnose a primary lipid disorder, you have to rule out poorly controlled diabetes, excessive alcohol intake, untreated hypothyroidism, tephotic syndrome, and notably medications. Oh, the medication list is a massive culprit. Hydose glucocorticoids, oral estrogens, thizide diuretics, and HIV pro-tese inhibitors are absolutely notorious for spiking triglycerides into the danger zone. And here is a phenomenal bedside parole that many residents learn the hard way during their ICU rotations. Yes, the ICU trap. Let's hear it. You are cross covering the medical ICU overnight. You have a patient admitted in Florida septic shock, secondary to pneumonia, intubated, and on two vasopressors. A well-meaning day team resident decided to draw a comprehensive metabolic panel and indiscriminately through in a standard lipid panel. Oh, no. The results pop up and the triglycerides come back at 8.50. Do you start pheno-fibrate down the feeding tube? Absolutely not. You never, ever trust a lipid panel drawn during an acute phase response. Severe systemic inflammation, massive cytokine release, and sepsis drastically ultra lipid metabolism. The inflammatory cascade profoundly suppresses lipoprotein lipase activity, essentially halting the clearance of triglyceride-rich lipoproteins from the blood. It is an expected physiological response to severe stress. Exactly. You ignore that lipid panel entirely, focus entirely on treating the septic shock and instruct the primary care doctor to recheck the lipids in the outpatient setting weeks after full recovery. That is exactly the diagnostic reasoning the boards are looking for. Now, for our final clinical segment, let's bring all of these nuanced guidelines, biomarkers, and complex pharmacology together. How do we apply everything we have discussed to our most frequently tested, most complex, special populations? Specifically, let's dissect the intersection of diabetes and statin therapy. Diabetes is the ultimate cardiovascular risk equivalent in the eyes of the board examiners. The fundamental rule is simple, yet heavily tested in various clinical vignettes. Any adult between the ages of 40 and 75 with a diagnosis of diabetes automatically earns at a bare minimum a moderate intensity statin. You do not need to pull out your phone and calculate a 10-year pre-vent score to justify the prescription. The diagnosis of diabetes alone is the absolute indication. But you cannot stop there. The nuance is in the risk stratification. You must evaluate the diabetic patients for additional ASCVD risk factors. If that same 40-75-year-old diabetic patient has hypertension, a history of smoking, evidence of albuminuria, or a calculated prevent score greater than 10%, you do not pass go with a moderate intensity statin. No, you must immediately escalate to a high intensity statin with the explicit targeted goal of driving their LDLC strictly below 70 milligrams per desoliter and their non-HDL below 100. Now, we have to address the massive elephant in the room regarding statins and diabetes. This is a topic completely riddled with internet misinformation, and the literature addresses it head on because it disrupts clinical care daily. We need to talk about the fear of statin-induced diabetes. The boards will test your fundamental understanding of this concept, and I guarantee your patients will interrogate you about it during their clinic visits. Oh, daily. The pathophysiology behind this phenomenon is complex and still being elucidated, but we do know the basic mechanisms. Statins work by up-regulating LDL receptors to pull cholesterol out of the blood. However, they also up-regulate LDL receptors on the pancreatic beta cells, leading to increased intracellular cholesterol accumulation within the eyelid cells. Oh, interesting. This accumulation can physically impair insulin secretion. Furthermore, high intensity statins can modestly increase peripheral cellular insulin resistance. So, the clinical translation is that in a patient who already has profound metabolic syndrome, meaning they have severe central obesity, elevated fasting glucose of 115, and are teetering right on the metabolic edge of the diabetic threshold, starting a high intensity statin can indeed push their hemoglobin A1C just over the line, right, from a prediabetic 6.2% into an overt diabetic 6.6%. Exactly. This physiological reality sets up a classic, multi-layered board trap that requires confident clinical judgment to navigate. Let's lay it out. The vignette will read like this. A 55-year-old patient with hypertension and obesity was started on a torvistatin 40-mg 6 months ago for primary prevention. They return for their routine follow-up. Their lipid profile is vastly improved. The APOB has plummeted, but their new hemoglobin A1C is 6.6%. It was 6.2% prior to initiating the statin. Right. The patient feels fine and is completely asymptomatic. What is the most appropriate next step in management? The distractors will look incredibly tempting to a cautious clinician. The options will include, discontinue a torvistatin and switch to aggressive lifestyle modifications. Decrease out of a set and dose to 10 milligrams. Switch therapy, defenetfibrate. Do not fall for it. The reality, backed by massive, rigorous meta-emalacies, is that you absolutely never stop the statin in the scenario. The mathematical trade-off is heavily weighted in favor of the statin. The absolute cardiovascular risk reduction, the definitive prevention of fatal ischemic strokes, and massive, necker energizing myocardial infarctions vastly, exponentially outweighs the microvascular harm of a slight, statin-induced bump in glycemic indices. The correct board answer is to maintain the high-intensity statin to guarantee cardiovascular protection and simultaneously initiate standard guideline-directed medical therapy for the new onset diabetes, starting with intensive lifestyle modifications and metformin. But translating that hard data into a palatable clinic conversation is an absolute art form. How do you actually counsel the highly hesitant skeptical patient who read a terrifying blog post online that claims statins cause high blood sugar and destroy your metabolism? Because if you simply dismiss their concern is internet nonsense, you instantly lose their trust, they will not politely walk out and silently throw the prescription in the trash. You have to validate their research and reframe the narrative entirely. I use exactly this phrasing when I am at the bedside. You know, you are absolutely right. The research article you read is factually correct. Statins can slightly raise blood sugar levels, and in some patients who are already at risk, it can bump them into the diabetic range. I'm glad you brought this up. That's a great start. Then I say, "But here is the critical reason why I'm still strongly recommending this medication for you. If we look at a room of 100 people with your exact health profile, the statin might cause a mild manageable increase in blood sugar in one or two of them, but in that exact same group of 100 people, that exact same statin will definitively prevent five massive life-altering heart attacks or strokes." That frames it perfectly. I finish with, "We can easily safely manage a slight bump in your blood sugar with diet modifications or a very safe, cheap medication like mitformin. I cannot easily fix a fatal heart attack that destroys a third of your heart muscle. The massive protection you get for your heart and your brain far outweighs the slight risk to your blood sugar." That is the perfect bedside pivot. It respects their intelligence. It acknowledges that the literature they read wasn't fabricated, but it firmly frames the clinical decision around catastrophic risk reduction. It turns a confrontational conversation into a collaborative one. We have covered an incredible amount of complex ground today. From retiring the archaic pooled cohort equations in favor of the modernized prevent calculator, to navigating the intricate pathophysiology and absolute goals of APAB and LPA, aggressively managing the genetic extremes of familial hypercholesterolemia, understanding exactly when and how to deploy benpidoric acid and ecosopenethyl, and confidently counseling through the complexities of diabetic dyslipidemia. Before we wrap up this installment of the A-Bim series, I want to leave you with a final, provocative thought to mull over during your next commute. Okay, let's hear it. We spent this entire time talking about optimizing daily pills, adjusting statin doses, adding is edema. But adherence remains one of the most massive, insurmountable hurdles and outpatient lipid management. Patients forget their daily statin, they experience mild, mild, just and stop the drug without telling us, or they just get pill fatigue. It happens all the time. But look at the breathtaking trajectory of the pharmacology right now. We are moving rapidly toward an era of RNA interference therapies. specifically agents like Inclycerin. Inclycerin is a marvel of modern molecular biology. It is a small interfering RNA or CERNA therapy. It acts directly at the intracellular level of messenger RNA to halt the translation and production of the PCS-K9 protein in the liver entirely. No PCS-K9 means massive upregulation of LDL receptors. And the most astonishing part of this technology, once the initial loading doses are complete, it requires a simple, subcutaneous injection in the clinic just twice a year. Exactly. So here's the existential question for primary care to explore. If lipid management transitions from a daily oral burden remembering to take a pill every single morning to a seamless, bi-annual injection administered by a nurse, will medication non-adherence for dyslipidemia become a historical footnote? That's a great question. And more profoundly, how will that fundamentally restructure the rhythm of our clinics? If you only need to see the high-risk cardiovascular patient twice a year for their lipid injection, does that open up our overwhelmed clinic schedules, or does it risk losing the frequent vital clinical touch points we rely on for holistic, comprehensive, preventative care? It is a fascinating paradigm shift on the horizon that goes beyond just lowering a number on a page. The technology is moving faster than our clinic models can adapt. Let's quickly synthesize the absolute must-know takeaways for the boards and the wards from this exhaustive discussion. Don't good. First, the pre-event equations have definitively replaced the PCE, significantly lowering the risk thresholds. Remember that 3% is now the absolute floor for borderline risk. Second, abandon the freedwold formula in extremes, use the Martin Hopkins equation for accurate LDL estimation, and rely on APOB as the ultimate tiebreaker for athergenic particle burden, especially an insulin-resistant metabolic syndrome. Love that. Third, strict absolute goals are back. Aim for less than 70 for primary prevention and high risk patients, and strictly less than 55 for secondary prevention. Do not back down on therapy. Finally, understand the precise mechanism of bimbadouac acid as your physiological liver-specific workaround for statin intolerance. Master those physiological concepts and clinical frameworks. And you will not only dominate this section of the boards, but you will provide truly exceptional evidence-based care at the bedside. Thank you for joining us for another rigorous discussion. Please be sure to like, share, and subscribe to evidence at the bedside so you never miss a critical update in internal medicine. We appreciate you learning with us today and advancing your clinical practice. Keep pushing the evidence to the bedside. We will see you next time.